|
|
|
|
Cancer Up Close
My two young sons and I spent months walking by the poster-size U.S.News & World Report magazine covers declaring Johns Hopkins as the best hospital while my husband was being treated there for malignant chondrosarcoma in 2004....
|
|
|
Methods and compositions for the treatment of angiogenic diseases
Provided are agents that can bind to copper, and form a tripartite complex with protein, and the use of these agents in the prevention and treatment of diseases with a vascular component, such as solid tumors.Compositions and methods for...
|
|
|
Oral Belinostat (PXD101) Promotes Stabilisation of Advanced Solid Tumours: Presented at EORTC-NCI-AACR
-- An oral form of the class 1 and 2 histone deacetylase inhibitor (HDAC) belinostat (PXD101) is well tolerated and can promote long stabilisation of disease in patients with advanced solid tumours, according to a multicentre, open-label,...
|
|
|
Myxoid chondrosarcoma in the pineal region Case report 904
You can also purchase online an Individual or Institutional Subscription to this journal or buy one or more printed volumes.An Individual Subscription to the journal grants: online access to all articles in the current volume a print copy...
|
|
|
'Cancer Research' Journal Publishes Successful Angiogenesis Study Using Optimata's Technology
- Optimata Ltd., developer of the proprietary Optimata Virtual Patient(R) technology to navigate drug development, announced today that a scientific paper based on research carried out by company scientists will be published in the...
|
|
|
'Cancer Research' Journal Publishes Successful Angiogenesis Study Using Optimata's Technology
RAMAT GAN, Israel & HOUSTON --(Business Wire)-- Optimata Ltd., developer of the proprietary Optimata Virtual Patient(R) technology to navigate drug development, announced today that a scientific paper based on research carried out by...
|
|
|
'Cancer Research' Journal Publishes Successful Angiogenesis Study Using Optimata's Technology
News source: Business Wire Optimata Ltd., developer of the proprietary Optimata Virtual Patient(R) technology to navigate drug development, announced today that a scientific paper based on research carried out by company scientists will be...
|
|
|
'Cancer Research' Journal Publishes Successful Angiogenesis Study Using Optimata's Technology
RAMAT GAN, Israel & HOUSTON--(BUSINESS WIRE)--Optimata Ltd., developer of the proprietary Optimata Virtual Patient technology to navigate drug development, announced today that a scientific paper based on research carried out by company...
|
|
|
'Cancer Research' Journal Publishes Successful Angiogenesis Study Using Optimata's Technology
Optimata Ltd., developer of the proprietary Optimata Virtual Patient(R) technology to navigate drug development, announced today that a scientific paper based on research carried out by company scientists will be published in the prestigious...
|
|
|
'Cancer Research' Journal Publishes Successful Angiogenesis Study Using Optimata's Technology
Optimata Ltd., developer of the proprietary Optimata Virtual Patient(R) technology to navigate drug development, announced today that a scientific paper based on research carried out by company scientists will be published in the prestigious...
|
|
|
'Cancer Research' Journal Publishes Successful Angiogenesis Study Using Optimata's Technology
www.optimata.com - Optimata Ltd.Daphna Lewin, +972-3-7519226 Business Development daphna@optimata.com Optimata Ltd., developer of the proprietary Optimata Virtual Patient(R) technology to navigate drug development, announced today that a...
|
|
|
'Cancer Research' Journal Publishes Successful Angiogenesis Study Using Optimata's Technology
Prof.Agur to Speak at M. Anderson Cancer Center Symposium on Oct. 30 M. Anderson Cancer Center's 61st Annual Symposium RAMAT GAN, Israel & HOUSTON--(BUSINESS WIRE)--Optimata Ltd., developer of the proprietary Optimata Virtual...
|
|
|
'Cancer Research' Journal Publishes Successful Angiogenesis Study Using Optimata's Technology
Business Editors/Health/Medical Writers/Technology Writers RAMAT GAN, Israel & HOUSTON--(BUSINESS WIRE)--October 27, 2008--Optimata Ltd., developer of the proprietary Optimata Virtual Patient technology to navigate drug development,...
|
|
|
Skeletal Osteochondromas Revisited
Describe the clinical signs and symptoms, imaging, and histological features of skeletal osteochondromas.List the different variants of skeletal osteochondromas. Discuss the indications of, for observation, as opposed to the operative...
|
|
|
Exelixis Reports Positive Phase 1 Data for PI3K/mTOR Inhibitor XL765 at EORTC-NCI-AACR Symposium
- Exelixis, Inc.(Nasdaq:EXEL) today reported interim data from a phase 1 dose-escalation trial of XL765, a novel small molecule inhibitor of PI3K and mTOR, which are implicated in tumor cell proliferation, survival, and resistance to...
|
|
|
Exelixis Reports Positive Phase 1 Data for PI3K/mTOR Inhibitor XL765 at EORTC-NCI-AACR Symposium
GENEVA--(BUSINESS WIRE)--Oct.22, 2008 - Exelixis, Inc. (Nasdaq:EXEL) today reported interim data from a phase 1 dose-escalation trial of XL765, a novel small molecule inhibitor of PI3K and mTOR, which are implicated in tumor cell...
|
|
|
Exelixis Reports Positive Phase 1 Data for PI3K/mTOR Inhibitor XL765 at EORTC-NCI-AACR Symposium
-Exelixis, Inc.(Nasdaq:EXEL) today reported interim data from a phase 1 dose-escalation trial of XL765, a novel small molecule inhibitor of PI3K and mTOR, which are implicated in tumor cell proliferation, survival, and resistance to...
|
|
|
Grade I chondrosarcoma of bone: the Munster experience
Streitburger A et al.- Intralesional resection of a grade I chondrosarcoma has a higher overall risk of local recurrence but is not associated with a poorer survival. This procedure can be recommended for stage I A tumours of the...
|
